New Developments for Optimal Management of Head and Neck Cancer

Bree, Remco de; Leemans, C. René

doi:10.1159/000079085

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early HNSCC can usually be managed successfully with either radiotherapy or surgery. However, two thirds of the patients with HNSCC present with advanced disease and are usually treated by a combination of surgery followed by chemotherapy or radiotherapy (1). Distant metastases usually occur late in the course of the disease.…”

mentioning

confidence: 99%

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Groot

Senft²,

Bree

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

The aim of the study was to define the cost-effectiveness of whole-body 18 F-FDG PET, as compared with chest CT, in screening for distant metastases in patients with head and neck squamous cell carcinoma (HNSCC). Methods: In a multicenter prospective study, 145 consecutive patients with high risk factors for distant metastases and scheduled for extensive treatment underwent chest CT and whole-body 18 F-FDG PET for screening of distant metastases. The cost data of 80 patients in whom distant metastases developed or who had a follow-up of at least 12 mo were analyzed. Cost-effectiveness analysis, including sensitivity analysis, was performed to compare the results of 18 F-FDG PET, CT, and a combination of CT and 18 F-FDG PET (CT 1 18 F-FDG PET). Results: Pretreatment screening identified distant metastases in 21% of patients. 18 F-FDG PET had a higher sensitivity (53% vs. 37%) and positive predictive value (80% vs. 75%) than did CT. CT 1 18 F-FDG PET had the highest sensitivity (63%). The average costs in the CT, 18 F-FDG PET, and CT 1 18 F-FDG PET groups amounted to e38,558 ($57,705), e38,355 ($57,402), and e37,954 ($56,801), respectively, in the first year after screening. CT 1 18 F-FDG PET resulted in savings between e203 ($303) and e604 ($903). Sensitivity analysis showed that the dominance of CT 1 18 F-FDG PET was robust. Conclusion: In HNSCC patients with risk factors, pretreatment screening for distant metastases by chest CT is improved by 18 F-FDG PET. The combination of 18 F-FDG PET with CT is the most effective, without leading to additional costs.

show abstract

mentioning

confidence: 99%

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Groot

Senft²,

Bree

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Moreover, second primary tumors frequently develop in these patients, at a rate of 2–3% per year. Treatment of recurrent and second primary tumors is particularly challenging, especially when radiotherapy is no longer an option because of previous irradiation or when the site has already been subjected to extensive surgery, mainly due to concerns about toxicity and effect on the quality of life (QOL), loss of function and cosmetic disfigurement [ 5 , 6 ]. In fact, only a few patients with locoregional recurrence can be salvaged by surgery or reirradiation.…”

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Enokida¹,

Tahara²

2021

Cancers

View full text Add to dashboard Cite

Despite recent advances in the development of chemotherapeutic drug, treatment for advanced cancer of the head and neck cancer (HNC) is still challenging. Options are limited by multiple factors, such as a prior history of irradiation to the tumor site as well as functional limitations. Against this background, electrochemotherapy (ECT) is a new modality which combines administration of an antineoplastic agent with locally applied electric pulses. These pulses allow the chemotherapeutic drug to penetrate the intracellular space of the tumor cells and thereby increase its cytotoxicity. ECT has shown encouraging efficacy and a tolerable safety profile in many clinical studies, including in heavily pre-treated HNC patients, and is considered a promising strategy. Efforts to improve its efficacy and broaden its application are now ongoing. Moreover, the combination of ECT with recently developed novel therapies, including immunotherapy, represented by immune checkpoint inhibitor (ICI)s, has attracted attention for its potent theoretical rationale. More extensive, well-organized clinical studies and timely updating of consensus guidelines will bring this hopeful treatment to HNC patients under challenging situations.

show abstract

Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial

Senft

Bree

Hoekstra

et al. 2008

Radiotherapy and Oncology

View full text Add to dashboard Cite

New Developments for Optimal Management of Head and Neck Cancer

Cited by 3 publications

References 23 publications

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial

Contact Info

Product

Resources

About

New Developments for Optimal Management of Head and Neck Cancer

Cited by 3 publications

References 23 publications

Chest CT and Whole-Body18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Chest CT and Whole-Body18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial

Contact Info

Product

Resources

About

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

Chest CT and Whole-Body¹⁸F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients